In re: Metoprolol Succinate End-Payor Antitrust Litigation, No. 06-cv-71 (D. Del.)

Kessler Topaz was co-lead counsel in a lawsuit which alleged that defendant AstraZeneca  prevented generic versions of Toprol-XL from entering the market by, among other things, improperly manipulating patent filings and filing baseless patent infringement lawsuits. 

As a result, AstraZeneca unlawfully monopolized the domestic market for Toprol-XL and its generic bio-equivalents.  After seven years of litigation, extensive discovery and motion practice, the case settled for $11 million.

D 610.822.2210